Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Modified Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects

Trial Profile

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Modified Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Solabegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Velicept Therapeutics
  • Most Recent Events

    • 26 Dec 2018 Status changed from recruiting to active, no longer recruiting.
    • 16 Oct 2018 According to a Velicept Therapeutics media release, enrollment in trial is progressing as planned.
    • 24 Jul 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top